Home > Cardiology > ESC 2019 > Conference highlights > Fewer deaths and hospitalisations in HF patients with SGLT2-inhibitor dapagliflozin

Fewer deaths and hospitalisations in HF patients with SGLT2-inhibitor dapagliflozin

Expert
Professor John McMurray, Glasgow, Scotland, United Kingdom
Conference
ESC 2019
Trial
DAPA-HF

Treatment with SGLT2-inhibitor dapagliflozin reduces the rates of death and hospitalisation in patients with heart failure and reduced left ventricular ejection fraction (HFrEF) with and without diabetes. Professor John McMurray (Glasgow, Scotland, United Kingdom) stated that the most important finding was the benefit in patients without diabetes.

The DAPA-HF trial investigated whether dapagliflozin would also be useful in treating established HF, even in patients without diabetes. A total of 4,744 HFrEF patients from 20 countries was enrolled and randomised to either dapagliflozin 10 mg once daily or matching placebo. Primary endpoint of the study was the composite of a first episode of worsening HF (defined as hospitalisation for HF, or HF requiring intravenous therapy) or death from cardiovascular (CV) causes. Apart from the treatment with dapagliflozin or placebo, patients received an angiotensin-converting enzyme inhibitor or an angiotensin receptor b...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on